Skip to main content
BDTX logo

BDTX · Black Diamond Therapeutics, Inc. · Executive Compensation

Track BDTX — free
$1.32 -0.07 (-4.69%)
Market Cap
$75.28M
Shares
57.47M
Volume · Nov 20 662.46K Avg daily vol (3M) 697.63K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Mark A. Velleca $2,234,919
Sergey Yurasov $1,352,097
Brent Hatzis-Schoch $1,282,245
Fiscal 2024
Executive Total
Mark A. Velleca $2,855,111
Sergey Yurasov $1,514,820
Brent Hatzis-Schoch $1,405,116
Fiscal 2023
Executive Total
Mark A. Velleca $2,949,854
David M. Epstein $2,019,206
Fang Ni $1,489,526
Sergey Yurasov $1,233,684
Fiscal 2022
Executive Total
David M. Epstein $1,644,857
Brent Hatzis-Schoch $911,227
Fang Ni $909,759
Fiscal 2021
Executive Total
David M. Epstein $5,090,225
Brent Hatzis-Schoch $2,022,309
Fang Ni $1,674,570
Fiscal 2020
Executive Total
David M. Epstein $3,868,216
Rachel Humphrey $2,979,288
Brent Hatzis-Schoch $1,527,044
Fiscal 2019
Executive Total
David M. Epstein $3,346,081

Executive changes

Person Change Filed
Erika Jones Appointed 2024-10-07
Fang Ni Terminated 2024-10-07
Shannon Campbell Appointed 2024-04-11
Prakash Raman, Ph.D. Appointed 2024-04-11
Wendy L. Dixon, Ph.D.
“Dr. Dixon’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
Resigned 2024-04-11
Alexander Mayweg, Ph.D.
“Dr. Mayweg’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
Resigned 2024-04-11
Rajeev Shah
“Mr. Shah’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
Resigned 2024-01-18
Mark Velleca, M.D., Ph.D. Appointed 2023-09-18
Mark A. Velleca Appointed 2023-09-18
David M. Epstein Terminated 2023-09-18
Mark A. Velleca, M.D., Ph.D. Appointed 2022-12-19
Robert A. Ingram
“Mr. Ingram’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
Resigned 2022-12-19
Wendy L. Dixon Appointed 2022-04-07
Brad Bolzon
“Dr. Bolzon’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
Resigned 2022-04-07
Erika Jones Appointed 2021-11-22
Fang Ni, Pharm. D. Appointed 2021-11-22
Thomas Leggett
“Mr. Leggett’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or procedures.”
Resigned 2021-11-22
Mark Velleca Appointed 2021-08-10
Christopher Roberts Resigned 2021-08-05
Elizabeth Buck Appointed 2021-08-05
Karsten Witt Appointed 2021-08-05

Leadership

Key facts CIK 1701541 CUSIP 09203E105 13F (30d) 118 filings 105 filers Visit website Investor relations